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The development of leukemia is a complex, multistep process that is not fully understood. Although many leukemias harbor chromosomal translocations and additional mutations that drive oncogenic transformation, non-genetic factors also contribute to leukemia development. We have demonstrated that the relative fitness of hematopoietic progenitor cells (HPC) has a major role in leukemogenesis. 1, 2 That is, the presence of normally functioning HPC can slow or eliminate leukemia development from a small pool of cells harboring an oncogene, whereas the presence of HPC that have impaired fitness enhances leukemogenesis. However, the importance of these findings seems to be underappreciated, perhaps because a clinically relevant model has not yet been demonstrated. We propose that a clinical correlate of our previous work is the development of treatmentrelated acute myelogenous leukemia (tAML) in patients who are treated with DNA-damaging agents, followed by myelosuppressive agents that impair the relative fitness of HPC. þ Tg mice. For immunopathological analysis, the pretreated slides were incubated for 60 min with anti-CD3e and anti-B220 primary antibodies. To visualize the anti-B220 binding, the slides were incubated for 30 min with FITC-conjugated anti-rat IgG and to visualize anti-CD3e binding, they were incubated with peroxidase-conjugated goat anti-rabbit IgG, after which the stain was developed using diaminobenzidine. Nuclei were counterstained with Mayer hematoxylin. Predominant CD45R/B220 þ B-cell lymphoma cells (fluorescent green) were observed. Arrows indicate B220-positive cells. (e) Wright-Giemsa staining of the peripheral blood (original magnification Â 100). Leukemia cells accounted for 7.2 ± 1.2% of white blood cells in the peripheral blood of 14-month-old MLL/AF4 þ Tg mice. (f) Fluorescence activated cell sorter analysis comparing peripheral blood from WT and MLL/AF4
þ Tg mice revealed the presence Letters to the Editor tAML is one of the most devastating side effects of cancer therapy and occurs in 2-15% of patients treated for cancer. 3 Clinical chemotherapeutics that act by inhibition of topoisomerase II (for example, etoposide and daunomycin) are known to induce MLL gene rearrangements associated with tAML. Depending on the treatment protocol, these drugs may be followed by other myelosuppressive drugs (for example, purine antimetabolites such as, 6-mercaptopurine (or historically, 6-thioguanine (6TG)) and/or antifolates such as methotrexate), which have also been associated with tAML. 4 Thus, it is possible that leukemia may be initiated by a topoisomerase inhibitor and promoted by subsequent therapy. We hypothesized that the administration of a clinically relevant chemotherapeutic would promote leukemia development from oncogene harboring HPC, in part, by impairing the relative fitness of normal HPC.
We used 6TG to model prolonged myelosuppression after chromosomal translocation resulting from DNA-damaging chemotherapy. To demonstrate impaired HPC fitness induced by 6TG, mice were treated with 6TG (administered in the drinking water) for 4 weeks, followed by bone marrow (BM) harvest and assessment of HPC fitness by colony-forming unit assay. Indeed, the numbers of colony forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte and colony forming unit-granulocyte, monocyte were reduced in the mice that were treated with 6TG as compared with the untreated mice (Supplementary Figure 1) . We next sought to develop a model of leukemogenesis in which a small fraction of transplanted cells harbored MLL-AF9, and recipient mice were treated with 6TG. To do so, BM from young MLL-AF9 knock-in mice 5 was harvested and mixed at 1:9 ratio with competitor BM from wild-type (WT) mice that express green fluorescent protein (GFP) and then transplanted into sublethally irradiated recipient mice (Figure 1a ). In this model, all donor cells are CD45.2 þ , which distinguishes them from recipient cells that are CD45.1 þ . Thus, the origination of any given cell can be determined using flow cytometry. Recipient animals were left untreated for 3 weeks to allow hematopoiesis to recover. Peripheral blood was then analyzed by complete blood count and flow cytometry, and animals were divided to receive 6TG or no treatment. One group of animals was transplanted with WT BM without MLL-AF9 þ BM and was treated with 6TG to control for toxic effects of the medication, consisting primarily of mild myelosuppression (Supplementary Figure 2) . Peripheral blood was analyzed every 2 weeks by complete blood count and flow cytometry. The percentages of GFP neg donor cells (preleukemic MLL-AF9 þ ) were consistently and substantially higher in the animals that received WT competitor BM and treated with 6TG as compared with the animals that received WT BM and were left untreated (analysis of variance, Po0.05; Figure 1b) . MLL-AF9 knock-in mice develop myeloproliferative disease (MPD) before succumbing to leukemia. 5 We used total white blood cell counts to monitor recipient mice for the development of MPD, which we defined as white blood cells of 25 000/ml on two consecutive complete blood counts. Consistent with the increase in the percentages of preleukemic MLL-AF9 þ cells, the 6TG-treated recipients of WT competitor BM cells developed MPD earlier than those recipients of competitor BM that were untreated (P ¼ 0.04; Figure 1c ).
To address the possibility that the relative fitness of normal HPC may have a role in the expansion of oncogene-bearing, preleukemic populations, we included recipient groups transplanted with BM from mice with mutated, non-functional hypoxanthine phosphoribosyltransferase (HPRT). 6 HPRT is required to activate 6TG into its cytotoxic metabolite, so HPC from these mice are resistant to treatment with 6TG (as evidenced by a lack of reduction in colony-forming unit formation after treatment with 6TG (Supplementary Figure 1) ). When treated with 6TG, recipients of HPRT mt BM competitors did not have as rapid a rise in the percentages of preleukemia cells (analysis of variance, Po0.05; Figure 1b) , and the development of MPD was significantly delayed as compared with recipients of WT competitor cells (Po0.006; Figure 1c) . Together, these data indicate that 6TG promotes the development of MPD by reducing the relative fitness of HPC and providing a relative advantage for oncogene-bearing cells.
In this model, the development of MPD heralded the onset of symptomatic leukemia. In two independent experiments, the overall survival of 6TG-treated recipients of WT competitor BM cells was shorter than that of recipients of competitor BM that were left untreated (Po0.0001; Figure 1d ). Consistently though, in 6TG-treated recipients, the presence of HPRT mt HPC prolonged overall survival compared with WT HPC (Po0.0001), suggesting that the presence of relatively fit HPC can, to some extent, slow leukemia development. Nonetheless, the 6TG-treated recipients of HPRT mt competitor BM cells succumbed to leukemia more rapidly and at greater penetrance than untreated recipients of WT or HPRT mt BM (Po0.0001), indicating that impaired HPC fitness is only one aspect of leukemia promotion by 6TG. Purine analogs are known to be immunosuppressive, thus the differences in the penetrance and rate of leukemia development among the experimental groups could be the result of differences in the presence of an intact immune system. To control for this possibility, we bred the HPRT mt mice with mice mutant in the a-T-cell receptor (TCR), which are immunocompromized because they have essentially no functional T cells. 7 The BM from the resulting double-mutant mice (HPRT mt TCR mt ) was then used as competition with preleukemic MLL-AF9 þ cells as before, and the recipients were treated with 6TG. These Letters to the Editor chimeric recipients were thus immunocompromized, but not because of 6TG suppression of T-cell function. Survival in these recipients was significantly longer in the 6TG-treated recipients of HPRT mt TCR mt BM, as compared with the 6TG-treated recipients of WT competitors (P ¼ 0.003), indicating that suppression of T-cell function does not alter the kinetics of leukemia promotion by 6TG in this model. Still, the effect of 6TG on other aspects of the immune system cannot be excluded from these experiments.
We next sought to determine whether a specific population of MLL-AF9 þ HPC maintained a proliferative/survival advantage in the context of 6TG treatment, contributing to the increase in preleukemia burden in these mice. To do so, three mice from each group were euthanized at 8 weeks after transplantation (5 weeks of treatment), and the BM was analyzed by flow cytometry for different populations enriched for early hematopoietic progenitors, including hematopoietic stem cells and multipotent progenitors, common myeloid progenitors and granulocyte-macrophage progenitors (Supplementary Figure 3) . Without treatment, MLL-AF9
þ HPCs have an advantage over WT HPCs, such that the majority of phenotypic HPCs are derived from the MLL-AF9 þ BM, even though they were transplanted as a small minority (Figure 2a) . Based on the data from peripheral blood at the 3-week time-point (Figure 1b) , this advantage is primarily in the reconstitution period after transplantation. However, in the context of 6TG treatment, preleukemic MLL-AF9
þ HPCs appear to have a greater advantage, particularly at the level of multipotent progenitor (Figure 2a) , suggesting that treatment with 6TG may promote the progression of leukemia by increasing the relative selective advantage of oncogene-bearing HPC over normal HPC. When HPCs from 6TG-treated recipients of HPRT mt BM were analyzed by flow cytometry, a dramatic difference in the percentages of non-oncogene-bearing cells was seen as compared with all other groups at the level of the hematopoietic stem cell, common myeloid progenitor and granulocyte-macrophage progenitor (Figure 2a) þ HPC was suppressed to the same extent as that of WT HPC cells (Figure 2b) . Furthermore, when cultured cells were assessed for apoptosis, MLL-AF9 þ and WT HPC had similar percentages of early and late apoptotic cells as measured by flow cytometry for annexin V and propidium iodide exclusion (Figure 2c) , indicating that the cultured MLL-AF9 þ cells are not inherently resistant to the cytotoxic effects of 6TG. The lack of protection is somewhat surprising, given that MLL-
AF9
þ cells have been shown to exhibit a diminished p53 response to DNA damage. 8 These data provide clinical relevance to an underappreciated aspect of leukemogenesis. That is, the relative fitness of nononcogene-initiated HPC influences the development and progression of leukemia. While our previous reports highlight the biologic importance of these findings, 1,2 we have now paired clinically relevant HPC impairment with leukemia initiation to emphasize the clinical relevance of this phenomenon. Future studies are designed to test other medications and oncogenes, and to further elucidate the mechanisms of the observed phenomena. Of course, prolonged treatment with myelosuppressive medications, including 6TG, is beneficial for the vast majority of patients for whom they are prescribed. However, this comes with some risk of impairing the fitness of normal HPC and allowing oncogene-initiated HPC a competitive advantage, compounding the potential of these drugs to induce leukemia. These risks should be carefully considered in the development of treatment protocols in which DNA-damaging agents may be given before prolonged myelosuppression. deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. pos/neg and negativity for CD13, CD34 and HLA-DR). Further characterization indicated that the leukemic clone in these patients did not express other myelomonocytic antigens and, on the molecular level, all patients were positive for the NPM1 type A mutation. Based on these findings, the authors suggested the presence of a homogeneous genetic background within this AML subgroup. The molecular definition is important to better characterize the heterogeneous group of patients with AML and to identify potential targets for accurate diagnosis, assessment of prognosis and improved treatment strategies. In this aspect, we were interested in this novel population and aimed to verify its existence in a cohort of AML patients investigated prospectively within the study alliance leukemia (SAL).
We performed routine leukemia diagnostics, including immunophenotyping, molecular and cytogenetic analyses, and cytomorphology in 1435 patients with AML enrolled in different multicenter studies of the SAL study group. Based on the immunophenotype described by Kern et al., 1 we identified a group of 29 patients (2.0%). In addition to the special immunophenotypic criteria and in line with the data reported by Kern et al.,
1 all of these patients had a normal karyotype, showed an increased median leukocytes count of 44 GPT/l (range: 2-267 GPT/l) and presented predominantly with cytomorphological characteristics of AML M1 (Table 1) . Furthermore, we looked for the presence of the cup-like morphology, 2 a distinct morphological subgroup having a nuclear invagination, and found that 75% of the analyzed patients showed this morphology, which is slightly higher than in the population described by the Munich group. In addition, the median age of our cohort was significantly lower than that described by Kern et al. 1 (53 versus 70 years, Po0.0001). The reported prevalence of NPM1 mutations in unselected patients with AML ranges from 25 to 35%. 3 In line with this, the overall prevalence of NPM1 mutations in the investigated AML patients enrolled in the above mentioned SAL studies was 30.8% (442/1435). The previous study by Kern et al.
1 found NPM1 mutations in all patients with AML-LD, However, when we correlated the flow cytometric data with the molecular analyses in our patients, only 27 of our 29 individuals showed NPM1 mutations in exon 12. To investigate the presence of mutations outside this region, we sequenced the NPM1-mRNA corresponding to exons 9-11. In one patient, we could indeed identify a 19 bp deletion mutation in exon 10, leading to a deduced frameshift starting at AA 252 and inducing a premature stop of translation at codon 265. In the second patient, no such mutation in NPM1 could be identified. However, a comparison of the immunophenotype of this patient including antigens like CD2, CD7 and CD19 indicated that this patient was the only one who expressed CD7 aberrantly, a marker that is rarely seen in AML with mutant NPM1 as recently reported 4 and confirmed in our updated data set of 538 AML patients (CD7 pos 13.1% wtNPM1 versus 5.0% mNPM1, P ¼ 0.0027; unpublished data). Thus, the inclusion of CD7, CD2 and CD19 negativity as criterion might further strengthen the special phenotypic subentity reported by Kern et al. Furthermore, within the patients with exon 12 NPM1 mutations, only 24/27 had a type A mutation, one additional patient had a type D mutation and two patients showed other NPM1 mutations (DD-3/CAGA and DD-43/CAAG). Based on these results, it appears more likely that not the type of NPM1 mutation but the presence of the mutation is associated with the development of this particular immunophenotype.
Taken together, our data clearly support Kern and et al. in their description of a novel subgroup of patients presenting with a distinct immunophentotypic, molecular and morphologic profile. However, our data also suggest that the NPM1 mutations present in this group are not restricted to the most common type A, but may include other exon 12 variants as well as rare mutations outside exon 12. In addition, the analysis of lymphocytic antigens like CD2, CD7 and CD19 might help to more precisely describe the relevant subpopulation.
In conclusion, our data support the presence of the distinct immunophenotypic subgroup first described by Kern et al.
1 with a prevalence of 2% in unselected AML patients. It will be interesting to see whether this subgroup could be further characterized by a particular clinical behavior. Preliminary data in our own cohort indicated that only 33% (7 of 21 evaluable patients) achieved a complete remission after conventional double induction, a rate that is significantly lower than observed in the entire population of patients with normal karyotype AML in the respective SAL studies (68.4%, 450/658 patients, P ¼ 0.002, Fisher's exact test). Although obtained from different protocols and based on small numbers, if these data could be confirmed independently, it would make the detection of this subgroup also relevant from a clinical point of view.
